small molecule

ALTRENO

TRETINOIN

Loss of exclusivityAugust 2038latest FDA-listed patent expiry
CompanyDOW PHARMACEUTICAL SCIENCES

Drug detail

Brand nameALTRENO
Active ingredientTRETINOIN
Strength0.05%
Dosage formLOTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalAugust 2018
Marketing statusRX

Listed patents

PatentExpiresType
10653656August 2038product
11324710August 2038use U-2368

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.